US 12,188,096 B2
Clear cell renal cell carcinoma biomarkers
Xiaosai Yao, Singapore (SG); Patrick Tan, Singapore (SG); Bin Tean Teh, Singapore (SG); Jing Tan, Singapore (SG); Huilin Shao, Singapore (SG); and Joanna Koh, Singapore (SG)
Assigned to AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, Singapore (SG); and Singapore Health Services Pte Ltd, Singapore (SG)
Filed by AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, Singapore (SG); and Singapore Health Services Pte Ltd, Singapore (SG)
Filed on Aug. 19, 2022, as Appl. No. 17/820,925.
Application 17/820,925 is a division of application No. 16/642,430, abandoned, previously published as PCT/SG2018/050450, filed on Sep. 5, 2018.
Claims priority of application No. 10201707218R (SG), filed on Sep. 5, 2017.
Prior Publication US 2023/0279496 A1, Sep. 7, 2023
Int. Cl. C12Q 1/6886 (2018.01); G01N 33/574 (2006.01)
CPC C12Q 1/6886 (2013.01) [G01N 33/57438 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01)] 18 Claims
 
1. A method of treating clear cell renal cell carcinoma (ccRCC) in a subject, comprising:
obtaining a renal sample from the subject;
screening the renal sample for the upregulation of a clear cell renal cell carcinoma (ccRCC) biomarker set compared with a control group, wherein the biomarker set comprises at least two biomarkers selected from the group consisting of ZNF395, SMPDL3A, SLC28A1, SLC6A3, VEGFA, and EGLN3, wherein one of the at least two biomarkers is SMPDL3A or SLC28A1, wherein the biomarkers are nucleic acids encoding the same proteins, or variants thereof, and wherein the variants are allelic variants, splice variants, species-specific homologs, paralogs, and/or orthologs;
identifying a subject as having ccRCC based on the upregulation of the biomarker set in the sample compared with the control group; and
treating the subject identified as having ccRCC with an effective amount of an anti-ccRCC compound and/or treatment.